Jonathan Young Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Key Points

• Akero Therapeutics COO Jonathan Young sold 12,500 shares of the company's stock on August 12th for a total of $597,375, reducing his holdings by 5.95%.
• The company's stock recently traded at $48.31, with a significant 52-week range between $21.34 and $58.40, indicating considerable volatility in its price.
• Analysts maintain a consensus "Buy" rating for Akero Therapeutics, with an average price target of $81.57, reflecting positive long-term outlooks.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 12,500 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $47.79, for a total value of $597,375.00. Following the transaction, the chief operating officer owned 197,484 shares of the company's stock, valued at $9,437,760.36. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jonathan Young also recently made the following trade(s):

• On Wednesday, June 18th, Jonathan Young sold 1,453 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.84, for a total transaction of $79,682.52.
• On Tuesday, June 10th, Jonathan Young sold 2,493 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.99, for a total transaction of $134,597.07.

Akero Therapeutics Stock Down 1.3%

Shares of NASDAQ AKRO traded down $0.67 during mid-day trading on Monday, reaching $48.72. 111,257 shares of the company were exchanged, compared to its average volume of 1,419,420. Akero Therapeutics, Inc. has a 1 year low of $21.34 and a 1 year high of $58.40. The firm has a 50-day moving average of $51.95 and a 200 day moving average of $47.22. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of -24.36 and a beta of -0.28. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.11. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. On average, research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new position in shares of Akero Therapeutics during the second quarter worth $28,000. Northwest & Ethical Investments L.P. purchased a new position in Akero Therapeutics during the 1st quarter worth $32,000. GF Fund Management CO. LTD. acquired a new position in Akero Therapeutics during the 4th quarter valued at about $41,000. Sterling Capital Management LLC raised its stake in Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Akero Therapeutics by 30.8% in the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on AKRO. Citigroup decreased their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. TD Cowen initiated coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a "buy" rating and a $76.00 target price for the company. Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a "buy" rating on the stock. Bank of America raised their price target on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Finally, Wall Street Zen raised shares of Akero Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $81.57.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.